| |
Lead-in period (2 weeks)
|
Isoenergetic period (2 weeks)
|
Ad libitum period (12 weeks)
|
Friedman tests
|
|---|
|
Physical activity (MET-h/d)*:
|
|
Control group (n = 13)
|
38.2 (19.9)
|
38.6 (22.7)
|
37.4 (21.7)
|
χ2(5) = 6.156, p = 0.291
|
|
n-3-PUFA3 group (n = 13)
|
54.8 (29.9)
|
62.0 (29.9)
|
57.5 (29.6)
|
χ2(5) = 7.313, p = 0.198
|
| | | | |
RM-ANOVA†
|
| | | | |
Time
|
Time × Group
|
|
Calorie intake (MJ/d):
|
|
Control group (n = 13)
|
10.9 (1.5)
|
10.9 (1.3)
|
10.2 (1.9)
|
F(1.1,26.4) = 2.994,
|
F(1.1,26.4) = 0.703,
|
|
n-3-PUFA group (n = 13)‡
|
11.0 (2.2)
|
11.1 (2.0)
|
10.7 (2.5)
|
p = 0.092
|
p = 0.555
|
| |
CRC 1 §
|
CRC 2
|
CRC 3
| | |
|
Resting energy expenditure (MJ/d):
|
|
Control group (n = 12)
|
6.74 (0.89)
|
6.41 (1.10)
|
6.41 (0.79)
|
F(2,46) = 0.313,
|
F(2,46) = 0.703,
|
|
n-3-PUFA group (n = 13)
|
6.53 (1.23)
|
6.59 (1.51)
|
6.57 (1.39)
|
p = 0.733
|
p = 0.500
|
|
Resting energy expenditure (kJ/d/kg fat free body mass ||):
|
|
Control group (n = 12)
|
134 (15)
|
-
|
132 (13)
|
F(1,23) = 0.002,
|
F(1,23) = 0.315,
|
|
n-3-PUFA group (n = 13)
|
133 (21)
|
-
|
135 (14)
|
p = 0.961
|
p = 0.580
|
|
Respiratory quotient:
|
|
Control group (n = 12)
|
0.86 (0.05)
|
0.87 (0.05)
|
0.86 (0.05)
|
F(2,46) = 0.096,
|
F(2,46) = 1.091,
|
|
n-3-PUFA group (n = 13)
|
0.85 (0.03)
|
0.84 (0.05)
|
0.85 (0.05)
|
p = 0.908
|
p = 0.344
|
- All data are means (SD). * MET-h, metabolic equivalent task-hours. † RM-ANOVA, repeated-measures analysis of variance. ‡ PUFA, polyunsaturated fatty acids. §CRC, Clinical Research Center. || Fat-free body mass data from dual-energy x-ray absorptiometry-scans were available only for CRC visits 1 and 3.
